Utilizza questo identificativo per citare o creare un link a questo documento: http://elea.unisa.it/xmlui/handle/10556/4473
Record completo di tutti i metadati
Campo DCValoreLingua
dc.contributor.authorRosamilio, Rosa
dc.contributor.authorGiudice, Valentina
dc.contributor.authorFerrara, Idalucia
dc.contributor.authorAnnunziata, Silvana
dc.contributor.authorPezzullo, Luciano
dc.contributor.authorVillani, Gaetano
dc.contributor.authorBaldi, Carlo Eugenio
dc.contributor.authorGuariglia, Roberto
dc.contributor.authorRocco, Mattia
dc.contributor.authorSelleri, Carmine
dc.date.accessioned2020-05-22T11:43:09Z
dc.date.available2020-05-22T11:43:09Z
dc.date.issued2016
dc.identifier.citationRosamilio R, Giudice V, Ferrara I, Annunziata S, Pezzullo L, Villani G, Baldi C, Guariglia R, Rocco, Selleri C. Prolonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatment. Translational Medicine @ UniSa 2016, 15(11): 80-83
dc.identifier.issnISSN 2239-9747it_IT
dc.identifier.urihttp://www.translationalmedicine.unisa.it/indexit_IT
dc.identifier.urihttp://elea.unisa.it:8080/xmlui/handle/10556/4473
dc.identifier.urihttp://dx.doi.org/10.14273/unisa-2671
dc.description.abstractT-large granular lymphocyte leukemia (T-LGLL) is a chronic clonal proliferation of effector memory cytotoxic CD3+CD57+CD56- T cells and the current guidelines suggest immunosuppressive therapy as first-line therapy, but the treatment of refractory/relapsed patients is still challenging due to the lack of prospective studies. We describe a series of two refractory/relapsed T-LGLL patients successfully treated with bendamustine, a chemotherapeutic agent largely used for B-cell neoplasms, but poorly investigated for the treatment of T-cell diseases. Complete remission (CR) was achieved in 3 and 6 months, respectively, and maintained for at least 20 months. One patient relapsed after a 20-month CR, but she was responsive to bendamustine therapy again, obtaining a further prolonged CR. Bendamustine as single agent or in combination could be a feasible therapeutic option in refractory/relapsed T-LGLL, especially for elderly patients because of its safety profile.it_IT
dc.format.extentP. 80-83it_IT
dc.language.isoenit_IT
dc.sourceUniSa. Sistema Bibliotecario di Ateneoit_IT
dc.subjectLGL leukemiait_IT
dc.subjectBendamustineit_IT
dc.subjectChemotherapyit_IT
dc.subjectSalvage therapyit_IT
dc.subjectImmunosuppressionit_IT
dc.titleProlonged complete hematologic response in relapsed/refractory T-large granular lymphocyte leukemia after bendamustine treatmentit_IT
dc.typeArticleit_IT
È visualizzato nelle collezioni:Translational Medicine @ UniSa. Volume 15 (may. - aug. 2016)

File in questo documento:
File Descrizione DimensioniFormato 
11.pdfTranslational Medicine @ UniSa. Volume 15 (may.-aug. 2016)461,99 kBAdobe PDFVisualizza/apri


Tutti i documenti archiviati in DSpace sono protetti da copyright. Tutti i diritti riservati.